MIRM FY2024 EPS Estimate Raised by Cantor Fitzgerald

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($1.69) for the year, up from their prior forecast of ($2.27). Cantor Fitzgerald currently has a “Overweight” rating and a $60.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.51) per share.

Other analysts also recently issued reports about the stock. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners raised their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Evercore ISI boosted their price target on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $57.73.

Mirum Pharmaceuticals Trading Down 3.8 %

NASDAQ:MIRM opened at $44.50 on Monday. The company has a market capitalization of $2.14 billion, a P/E ratio of -22.03 and a beta of 1.16. The stock’s 50 day moving average price is $40.12 and its 200 day moving average price is $36.15. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.09 and a current ratio of 3.34. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business’s revenue was up 89.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.57) EPS.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in shares of Mirum Pharmaceuticals by 11.7% during the 1st quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock worth $439,000 after purchasing an additional 1,825 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in Mirum Pharmaceuticals by 220.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 160,000 shares of the company’s stock valued at $4,019,000 after buying an additional 110,000 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Mirum Pharmaceuticals by 37.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock valued at $40,131,000 after buying an additional 432,824 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in shares of Mirum Pharmaceuticals by 64.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock worth $4,090,000 after acquiring an additional 63,871 shares during the period. Finally, Janus Henderson Group PLC boosted its position in shares of Mirum Pharmaceuticals by 34.2% during the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock valued at $69,470,000 after acquiring an additional 704,659 shares in the last quarter.

Insider Activity

In other news, SVP Jolanda Howe sold 2,500 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00. Following the transaction, the senior vice president now owns 2,426 shares in the company, valued at approximately $114,264.60. The trade was a 50.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.